Drug intelligence / Profile preview

NT-I351

Development stage: Preclinical
Lead developer: Numiera Therapeutics
Modality: Small Molecules

Overview

NT-I351 is a small molecule therapeutic candidate being developed by Numiera Therapeutics for the treatment of breast cancer and prostate cancer. As part of Numiera's pipeline, which focuses on modulating cancer cell metabolism—specifically fatty acid oxidation—NT-I351 is currently in the lead development stage. While its specific molecular target has not been publicly disclosed, it follows the company's lead asset, etomoxir, which is a known inhibitor of carnitine palmitoyltransferase 1 (CPT1).

Targets

SLC7A1 (Cationic amino acid transporter 1)

Beyond the preview

Go deeper on NT-I351.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NT-I351.

Explore the full profile